Last reviewed · How we verify
Apatinib+Capecitabine
Apatinib inhibits vascular endothelial growth factor receptor 2 (VEGFR2) to block tumor angiogenesis, while capecitabine is a fluoropyrimidine that inhibits thymidylate synthase to disrupt DNA synthesis in cancer cells.
Apatinib inhibits vascular endothelial growth factor receptor 2 (VEGFR2) to block tumor angiogenesis, while capecitabine is a fluoropyrimidine that inhibits thymidylate synthase to disrupt DNA synthesis in cancer cells. Used for Gastric cancer or gastroesophageal junction cancer (in combination), Other solid tumors under investigation in phase 3 trials.
At a glance
| Generic name | Apatinib+Capecitabine |
|---|---|
| Also known as | apatinib, capecitabine |
| Sponsor | Huazhong University of Science and Technology |
| Drug class | Tyrosine kinase inhibitor + Fluoropyrimidine antimetabolite |
| Target | VEGFR2 (apatinib); Thymidylate synthase (capecitabine) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Apatinib is a tyrosine kinase inhibitor that selectively targets VEGFR2, preventing new blood vessel formation that tumors depend on for growth and metastasis. Capecitabine is a prodrug that converts to 5-fluorouracil in tumor tissue, interfering with nucleotide synthesis and DNA replication. The combination leverages anti-angiogenic and cytotoxic mechanisms to enhance anti-tumor efficacy.
Approved indications
- Gastric cancer or gastroesophageal junction cancer (in combination)
- Other solid tumors under investigation in phase 3 trials
Common side effects
- Hypertension
- Hand-foot skin reaction
- Diarrhea
- Fatigue
- Nausea/vomiting
- Proteinuria
Key clinical trials
- Fluorizoparib Plus Apatinib Versus Chemotherapy in HRD-positive, HER2-negative Advanced Breast Cancer (PHASE3)
- A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma (PHASE2, PHASE3)
- Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma (PHASE2)
- A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy (PHASE3)
- A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study (PHASE2)
- Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer (PHASE3)
- Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping (PHASE2)
- Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Apatinib+Capecitabine CI brief — competitive landscape report
- Apatinib+Capecitabine updates RSS · CI watch RSS
- Huazhong University of Science and Technology portfolio CI